Notable Labs, Ltd.

Equities

NTBL

IL0012002452

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
0.97 ^USD	+1.04%		-19.83%	-48.68%

Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	MT
Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	MT

Vascular Biogenics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 17, 2022 at 07:00 am EDT

Vascular Biogenics Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.113 million compared to USD 0.185 million a year ago. Net loss was USD 10.43 million compared to USD 6.28 million a year ago. Basic earnings per share from continuing operations was USD 0.13 compared to USD 0.12 a year ago. Diluted earnings per share from continuing operations was USD 0.13 compared to USD 0.12 a year ago.

Latest news about Notable Labs, Ltd.

Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	Apr. 15	MT
Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	Apr. 15	MT
Notable Labs, Ltd. Presents the Design Plan for the Ppmp-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024	Apr. 09	CI
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay At AACR 2024 Expands the Potential of the Platform	Apr. 08	CI
Notable Labs, Ltd. Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment	Feb. 22	CI
Top Premarket Gainers	Jan. 09	MT
JMP Securities Cuts Notable Labs' Price Target to $9 From $13, Keeps Market Outperform Rating	Dec. 19	MT
Notable Labs, Ltd. and CicloMed LLC Announces Initial Safety and Efficacy Data of Fosciclopirox and the Performance of PPMP	Dec. 18	CI
Transcript : Notable Labs, Inc., Vascular Biogenics Ltd. - M&A Call	23-10-17
Vascular Biogenics, Notable Labs Complete Merger	23-10-16	MT
Vascular Biogenics Ltd.(NasdaqCM:VBLT) dropped from NASDAQ Composite Index	23-10-16	CI
Notable Labs, Inc. completed the acquisition of Vascular Biogenics Ltd. from Aurum Ventures MKI Ltd. and others in reverse merger transaction.	23-10-15	CI
Vascular Biogenics Ltd. Approves Board Appointments	23-10-12	CI
Vascular Biogenics Ltd. has Changed its Name to Notable Labs, Ltd	23-10-12	CI
Vascular Biogenics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Vascular Biogenics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Vascular Biogenics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
An unknown buyer completed the acquisition of Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd..	23-03-08	CI
Aleph Farms Limited completed the acquisition of manufacturing facility in Israel from Vascular Biogenics Ltd..	23-03-08	CI
Sector Update: Health Care Stocks Finishing with Small Rise	23-02-23	MT
Sector Update: Health Care	23-02-23	MT
Top Midday Gainers	23-02-23	MT
Transcript : Notable Labs, Inc., Vascular Biogenics Ltd. - M&A Call	23-02-23
Vascular Biogenics, Notable Labs Sign Merger to Form Nasdaq-Listed Therapeutic Platform Company	23-02-23	MT
Notable Labs, Ltd. announced that it has received $10.3 million in funding from Y Combinator Management, LLC, Builders VC, LLC, B Capital Group Management, L.P., First Round Capital Management, LLC, The Founders Fund, LLC	23-02-22	CI

Chart Notable Labs, Ltd.

Duration

Period

More charts

Company Profile

Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.97 USD

Average target price

8 USD

Spread / Average Target

+724.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NOTABLE LABS, LTD.	-48.68%	8.75M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs